Endometriosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Endometriosis Type, By Diagnostic Method, By Treatment Method, By Drug Category, By Diagnostics Type, By Distribution Channel, By End-User, Company, Region

The global endometriosis therapeutics market is expected to increase appreciably through 2027. Endometriosis is a disorder characterized by the tissues like the covering of the uterus growing on the outer part of the uterus. It is a type of chronic disease led to serve life-impacting pains during periods, sexual intercourse, urination, chronic pelvic pain, abdominal bloating, nausea, and fatigue. Sometimes extreme levels of these disorders can result in depression, anxiety, and infertility. Across the globe, various initiatives are going to make people, majorly women, aware of the problem; there are many off-label practices due to lack of information. In developing countries, the cost of therapy is creating restrain in growth.

According to WHO, almost 10% of reproductive-age women will be affected by this syndrome or disease globally in 2021. Different government organizations and NGOs are running global campaigns to create Awareness. Launching new advanced products and therapies, Awareness about continuous improvement in patients, and improvement in non-invasive diagnostic methods are one of the major factors responsible for the market. Thus, we can expect a rise in growth and demand in the market share of Endometriosis therapeutics in 2027.

Growing Awareness About the Disease and Treatment in Society

The increasing pervasiveness of gynecological and chronic diseases, an increasing number of people suffering from endometriosis, ongoing R&D activities for advanced endometriosis treatment, and rising demand for hormonal therapies & novel drugs are factors responsible for the growth of the Endometriosis Therapeutics Market. As the population increases, the demand for medical treatment and equipment is increasing in various parts of the world. According to the WHO report, in 2021, almost 190 million reproductive women and girls will be affected by endometriosis worldwide. The above data shows that there is massive potential in the market as the number of potential customers is in the millions and continues its grow as the population increases in developing countries; patients are still not aware of endometriosis and take the wrong drugs and treatment when there are any health problems. Thus, different initiatives and awareness program are going on through social media, Online platforms, newspapers, and other means. Therefore, growing awareness about endometriosis can positively impact the market share.

The large number of women worldwide suffering from endometriosis led to increased demand for treatment. Due to its positive outcome, patients are suggesting the treatment to another patient, and this word of mouth are most impactful in term of awareness. Hence, this factor can positively impact the market share. These increasing demands make the player work for significant technological Advancement in therapeutics and improving treatment. Technological Advancement in segments helps the doctor to treat the patient with minimal surgical cuts on the body, less painful processes, and shorter recovery time. All these efforts make the method more in demand and market share.

Various community, government, and community initiatives are running to uplift women's health. Australia has funded 58 million for improving endometriosis under the national action plan. Janani Shishu Suraksha Yojana, National action plan, Women’s health alliance is an example of global initiatives. These policies led to increasing demand for endometriosis therapeutics in the market. All the factors mentioned above are expected to drive the growth of the Endometriosis Therapeutics Market.

Off-Label Medication Practices are Hurdle in Growth

After so many awareness campaigns are running over the world, many people are still not reachable. Forget about the treatment. They are unaware of endometriosis and take treatment for another problem. Apart from this, in poorer countries, therapy costs are costly that restrain the market growth.

Continuous R&D for Advance Drug Technology is Driving Growth

The evolution of methods and drugs due to technological advancement per market requirements is expected to create impressive growth in the Endometriosis Therapeutics Market. Market players are proposing novel transdermal drug delivery technologies such as topical applicators to overcome the side effects of oral contraceptives and improve efficiency as many women sufferings from endometriosis increase the demand for treatment.

In 2022, Myovant science Limited and Pfizer LLC. Is collaborate and continued to jointly commercialize MYFEMBREE. This medicine is expected to help both companies combine their expertise to deliver the drug quickly and gain market size.

In 2022, Astellas Pharma Inc. announced the outcome of the drug, which is clinical trial version Phase 3, “SKYLIGHT 4“. It is a non-hormonal composite studied for treating sensible to severe vasomotor symptoms associated with menopause (VMS) which will encourage future regulatory organizing submissions.

Market Segmentation

The global endometriosis therapeutics market is segmented based on endometriosis type, diagnostic method, therapeutic method, distribution channel, and end user type. Based on endometriosis type, market is divided into superficial peritoneal lesion, endometrioma, deeply infiltrating endometriosis therapeutics. Based on diagnostic method, market is divided into ultrasound, pelvic examination, laparoscopy, magnetic resonance imaging, and others. Based on treatment method, market is split into hormonal therapy, and pain management. Based on drug category, market is divided into oral contraceptives, progestins, NSAIDs, GnRH analogues, and others. Based on diagnostics type, market is split into pure medical imaging v/s general laboratory use. Based on distribution channel, market is divided into retail pharmacies, hospital pharmacies, online pharmacies. Based on end user, market is divided into hospitals & clinics, ambulatory care center, and others, by company.

Market Players

The Abbott Laboratories, Inc. ; AbbVie, Inc.; Bayer AG; Pfizer, Inc.; Ipsen SA; Evotec SE; Myovant Sciences Ltd.; Philogen S.p.A.; Astellas Pharma Inc.; Orphagen Pharmaceuticals, Inc. are the major market player operating in the Endometriosis Therapeutics Market.

Report Scope:

In this report, global Endometriosis Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Endometriosis Therapeutics Market, by endometriosis type:

• Superficial Peritoneal Lesion
• Endometrioma
• Deeply Infiltrating Endometriosis Therapeutics

Endometriosis Therapeutics Market, by diagnostic method:

• Ultrasound
• Pelvic Examination
• Laparoscopy
• Magnetic Resonance Imaging
• Others

Endometriosis Therapeutics Market, by treatment method:

• Hormonal Therapy
• Pain Management

Endometriosis Therapeutics, by drug category:

• Oral Contraceptives
• Progestins
• NSAIDs
• GnRH Analogues
• Others

Endometriosis Therapeutics, by distribution channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Endometriosis Therapeutics Market, by end user type:

• Hospitals & Clinics
• Ambulatory Care Center
• Others

Medical market, By Region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• Europe & CIS
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Egypt
• Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Endometriosis Therapeutics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.

This product will be delivered within 1-3 business days.